Pharma & Biotech
-
CSL Behring Partners with Uplifting Athletes for Rare Disease Research and Honors Those Making an Impact
At the celebratory event, presented by global biotherapies leader CSL Behring, Uplifting Athletes awarded $180,000 in research grants to nine promising young investigative rare disease researchers and honored the six newest members of the organization’s Rare Disease Championship Team―an exemplary group of college football players who support Uplifting Athletes’ mission to inspire the Rare Disease Community…
-
Private Investors Buy $25M in NRx Stock for Radnor Firm’s COVID Research
Undisclosed investors are purchasing 7.8 million shares of NRx Pharmaceutical stock, raising $25 million to finance the Radnor company’s development of therapy and a vaccine for COVID-19, writes John George for Philadelphia Business Journal. The biopharmaceutical company entered into definitive agreements with the investors to purchase NRx common stock at $3.195 per share. Each share…
-
Jennifer Aniston Works on Commercial for Radnor Pharmaceutical Idorsia
Actress Jennifer Aniston talks about her struggles with insomnia in a commercial for Swiss pharmaceutical company Idorsia, writes John George for Philadelphia Business Journal. Idorsia has its U.S. operations in Radnor. The television and online commercials start Monday and run a week after Idorsia received clearance from the U.S. Food and Drug Administration to market…
-
NRx in Radnor Now Seeks Patent for COVID Drug Zyesami, Sees Other Uses
NRx Pharmaceuticals has now added a patent application to its paperwork for the COVID-19 therapy drug Zyesami, writes John George for Philadelphia Business Journal. Earlier this week, the Radnor biopharmaceutical company applied to the U.S. Food and Drug Administration for an emergency use of Zyesami to treat patients with critical COVID-19 and respiratory failure. The…
-
NRx in Radnor Asks Again for Approval to Use Its COVID-19 Drug, Zyesami
NRx Pharmaceuticals out of Radnor has once again filed an application with the Food and Drug Administration for emergency use of its experimental COVID-19 drug candidate, Zyesami, writes John George for Philadelphia Business Journal. The drug would be used on critical patients with COVID-19 who are at immediate risk of death from respiratory failure and…
-
Promising Results From COVID Drug Pushes Up Radnor Pharm’s Stock
Patients treated with an NRx Pharmaceuitcals drug candidate targeting COVID-19 showed “substantial improvement,” an analysis shows. The news caused the Radnor company’s stock to jump 20% Monday, writes John George for Philadelphia Business Journal. The patients had critical COVID-19 and respiratory failure but showed “substantial improvement” when given the NRx drug Zyesami. …
-
Thanks to John Furey of Bryn Mawr Being ‘Hands-On’, Bio-Tech Firm Triples in Size
It seemed the right thing for John Furey to do—take 20 years of experience in different pharma roles, including as COO of Spark Therapeutics, and become an advisor to various companies. But Imvax Chief Executive Officer John Furey of Bryn Mawr soon realized his passion was to stay hands-on, writes Elaine Quilici for pharmexec.com. “I…
-
Haverford Man Named Director of B.Labs, a Unique Life Science Research Facility
Matthew F. Burkhardt , a Haverford native, has been named the first director of the new life sciences incubator B.Labs, a partnership between the Pennsylvania Biotechnology Center of Bucks County and Brandywine Realty Trust, writes John George for Philadelphia Business Journal. B.Labs open in University City in January. B.Labs will have innovation, collaboration and research…
-
Radnor’s Avantor Acquires Lab Product Maker in Multi-Billion Dollar Deal
Laboratory equipment supplier Avantor is completing a $2.9 billion dollar deal to buy the product line of an Illinois-based pump manufacturer, writes John George for the Philadelphia Business Journal. The Radnor-based company is acquiring the Masterflex bioprocessing business of Antylia Scientific in Vernon Hills, Illinois. It’s a global maker of peristaltic pumps and aseptic single-use fluid transfer…
-
NRx in Radnor Has Stock Sale to Raise Funds for COVID Drug, Vaccine Research
A Radnor pharmaceutical company , NRx, active in COVID-19 research is entering into a multi-million dollar private stock sale, writes John George for Philadelphia Business Journal. The company has agreements with a group of unidentified investors. They will purchase $30 million of the company’s stock. . NRx will sell up to 2.73 million shares of…
-
Mobilion in Chadds Ford’s Raises Funds for Biomarker to Detect Disease
The Delaware County life sciences company Mobilion, that recently launched its first product, has raised $60 million through a private stock sale, writes John George for Philadelphia Business Journal. Mobilion Systems Inc.’s, which employs 60 people, previously raised $50.4 million from two investment rounds in 2019 and 2020. Founded in 2015, Chadds Ford-based Mobilion is…
-
NRx in Radnor Cleared to Use Its COVID-19 Drug in Country of Georgia
With COVID-19 cases growing by 1,000 cases a day, the country of Georgia has issued an emergency authorization to use a COVID-19 therapy, Zyesami, developed by NRx, a Radnor pharmaceutical company, writes John George for Philadelphia Business Journal. The emergency authorization came from Georgia’s prime minister and minister of health. With the rise in cases,…
-
ArriVent Launches in Newtown Square With Plans for New Cancer Drug
There’s a new biopharmaceutical company in town, specifically, in Newtown Square, writes John George for the Philadelphia Business Journal. ArriVent Biopharma of Newtown Square launched June 30. It’s backed by Series A financing that could provide up to $150 million. It received $90 million upfront in a private stock sale led by Hillhouse Capital Group.…
-
ESPN: Strokes of Genius: Abington Olympic Gold-Medalist Rower and Her mRNA- Expert Mom Race to the Top of Their Careers
For Susan Francia, a two-time Olympic gold medalist in rowing and daughter of newly-famous Abington scientist Dr. Katalin Kariko, hard work was always a part of life, she wrote for ESPN. She was taught by her mother that if she embraced hard work, it would bring her rewards in life. This philosophy turned true for…
-
Abington Scientist Who Pioneered COVID-19 Vaccine Research Believes mRNA Technology is Capable of Fighting Many Diseases
While even the majority of scientists working on mRNA vaccines for COVID-19 were shocked by its effectiveness, Katalin Karikó, an Abington biochemist and one of the pioneers of mRNA technology research, did not expect anything less, writes Stephen Buranyi for the WIRED. “There was no nail biting,” she said. “I expected the vaccines to be…
-
Radnor Biopharma Firm Looks at Hormone Targeting to Treat Hypertension
Mineralys Therapeutics in Radnor is on its way to developing a drug that will selectively treat hypertension, writes Laura Brzyski for Philadelphia Magazine. Mineralys Therapeutics is a private, biopharmaceutical company focused on hypertension and comorbidity disorders. It is part of a group of companies seeking novel biotechnology and healthcare solutions created by the venture capital…
-
Exton-Based Biotech Company’s Stock Balloons After Discovering Antibodies That Neutralize COVID-19 Variants
Immunome saw its stock soar after the Exton-based company discovered antibodies that have shown, in early testing, the ability to neutralize multiple variants of COVID-19, writes John George for the Philadelphia Business Journal. The company’s shares soared to an all-time high at one point after the announcement to reach $64 before tapering off and settling…
-
Done Deal: Malvern Company to Co-Develop COVID-19 Vaccine for U.S. Market
Malvern-based Ocugen has finalized a deal with Bharat Biotech to develop the India-based company’s COVID-19 vaccine, Covaxin, for the U.S. market, writes John George for the Philadelphia Business Journal. Ocugen first announced it was working on the deal in December. When the deal was finalized, the company’s stock went up by $0.57 per share to…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
